Company & Product

EG 427 is a French biotech company pioneering a new approach to precision gene therapy. 

Its unique platform, based on the non-replicating Herpes Simplex Virus type 1 (HSV-1) vector, enables, with surgical precision, highly selective and long-lasting expression of disease-modifying transgenes for the treatment of disorders of the peripheral nervous system and beyond. The first targets in the peripheral nervous system are C-type sensory neurons. The lead product, EG110A, targeting these neurons, is in preclinical development for the treatment of neurogenic bladder dysfunction (NBD). It is scheduled to enter the clinic in early 2024. 

Business

The company's research capabilities are focused on ensuring that this powerful platform approach has broad applicability, with potential for numerous products in several therapeutic areas with significant unmet medical needs.

This revolutionary approach to treating NVD aims to provide patients with a comprehensive, long-term solution to bladder management, through highly selective molecular surgery that overcomes the significant drawbacks of current standard of care.

Phases & Scope

Waiting for info​​​

Project Organization

Waiting for info​​​

​